LCN2 and COVID-19: In a prospective study, 19 urinary biomarkers were assessed to predict AKI in COVID-19 patients; among them, twofold higher levels of NGAL (HR, 1.34 [95% CI, 1.14–1.57]), monocyte chemoattractant protein (MCP-1) (HR, 1.42 [95% CI, 1.09–1.84]), and KIM-1 (HR, 2.03 [95% CI, 1.38–2.99]) were associated with the highest risk of sustaining a primary composite outcome (KDIGO stage 3 AKI, requirement for dialysis, or death within 60 days of hospital admission) (14).